Alzheimer's Drug PMN310 Shows Clean Safety Profile and Early Biomarker Shifts at 6 Months
A Phase 1b trial of PMN310 reports no serious adverse events and promising tau biomarker declines in 136 Alzheimer's patients.
Summary
ProMIS Neurosciences has shared six-month interim results from its PRECISE-AD trial testing PMN310, an antibody targeting toxic amyloid-beta oligomers in early Alzheimer's disease. Among 136 blinded patients, there were no serious treatment-related adverse events, no drug-related dropouts, and critically, no cases of brain swelling — a dangerous side effect seen with similar drugs. About 69% of patients showed a decline in a key blood-based tau marker, and 63% showed a decline in a spinal fluid tau marker, suggesting the drug may be affecting disease biology. The trial includes a high proportion of APOE4 carriers, a genetic group at elevated Alzheimer's risk. Full 12-month results are expected in early 2027.
Detailed Summary
Alzheimer's disease remains one of the most urgent targets in longevity medicine, with current approved therapies offering modest benefits and significant safety concerns. ProMIS Neurosciences has released encouraging six-month interim data from PRECISE-AD, its Phase 1b trial of PMN310 — an antibody designed to selectively neutralize toxic amyloid-beta oligomers without binding to amyloid plaques.
The safety profile stands out immediately. Among 136 blinded participants with mild cognitive impairment or mild Alzheimer's disease, the trial recorded zero cases of amyloid-related imaging abnormalities with edema (ARIA-E), and only 4.4% ARIA-H events, all mild. There were no treatment-related serious adverse events and no drug-related discontinuations. This compares favorably to lecanemab and donanemab, where ARIA rates — including serious cases — have been a limiting concern.
On the biomarker front, 68.5% of patients showed a decline from baseline in plasma pTau217, and 62.5% showed a decline in CSF MTBR-tau243. The company interprets these trends as early signals consistent with drug activity, noting the 3:1 active-to-placebo randomization makes population-level declines suggestive. Tau biomarkers are increasingly recognized as meaningful indicators of Alzheimer's progression and neurodegeneration.
Importantly, the trial population included 61% APOE4 carriers — a genotype associated with higher Alzheimer's risk and greater ARIA susceptibility — making the clean safety data more meaningful. Eleven percent were homozygous APOE4, a particularly high-risk subgroup often excluded from or underrepresented in trials.
Caveats are significant. This is a blinded interim analysis from a Phase 1b trial; efficacy conclusions cannot yet be drawn. The company's characterization of biomarker movement as reflective of drug effect is speculative at this stage. Twelve-month topline data, expected Q1 2027, will be critical for assessing whether biomarker changes translate to clinical benefit.
Key Findings
- Zero cases of ARIA-E brain swelling reported across 136 blinded Alzheimer's trial participants at six months.
- 68.5% of patients showed declining plasma pTau217, a key Alzheimer's progression biomarker.
- 62.5% of patients showed declining CSF MTBR-tau243, indicating possible neurodegeneration slowing.
- 61% of participants carried APOE4, the highest-risk Alzheimer's gene, with clean safety results across this group.
- No treatment-related serious adverse events or drug-related discontinuations reported in the trial.
Methodology
This is a news report summarizing company-issued interim trial results from a blinded Phase 1b study. The source is Longevity.Technology, a credible industry publication. Evidence is preliminary and company-reported; independent peer review and unblinded data are not yet available.
Study Limitations
Results are from a blinded interim analysis and cannot distinguish active drug from placebo at the individual level. Biomarker declines are characterized by the company as promising but remain speculative without unblinded efficacy data. Full topline results are not expected until Q1 2027, and Phase 1b trials are not powered to confirm clinical efficacy.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: